Discussion
Innovent Biologics, a China-based biopharmaceutical company, is planning to launch a Phase 2 clinical trial testing its experimental therapy IBI355 in people with Sjögren’s disease. The study will be conducted in China and is expected to launch in early 2027, according to a press release from Innovent…